Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and Launch

DOI: 10.1111/cts.12455
Clinical and Translational Science, 2017, 10, 84-92.

#	Paper	IF	Citations
87	Translating Precision. *Clinical and Translational Science*, **2017**, 10, 56-57	4.9	
86	Prediction of Anti-cancer Nanotherapy Efficacy by Imaging. *Nanotheranostics*, **2017**, 1, 296-312	5.6	53
85	Atezolizumab in advanced non-small cell lung cancer. *Journal of Thoracic Disease*, **2017**, 9, 3603-3606	2.6	6
84	Reproducibility of PD-L1 assessment in non-small cell lung cancer-know your limits but never stop trying to exceed them. *Translational Lung Cancer Research*, **2017**, 6, S51-S54	4.4	7
83	Using Genome Sequence to Enable the Design of Medicines and Chemical Probes. *Chemical Reviews* , **2018**, 118, 1599-1663	68.1	51
82	A hindsight reflection on the clinical studies of poly(l-glutamic acid)-paclitaxel. *Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology*, **2018**, 10, e1497	9.2	18
81	The importance of PD-L1 diagnostic assay harmonization for the selection of lung cancer immunotherapy. *Journal of Thoracic Disease*, **2018**, 10, S4096-S4100	2.6	3
80	Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden. *OncoImmunology*, **2018**, 7, e1526613	7.2	40
79	Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. *Tuberculosis and Respiratory Diseases*, **2018**, 81, 29-41	3.2	12
78	Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy. *Theranostics*, **2018**, 8, 3559-3570	12.1	59
77	Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice. *Future Oncology*, **2018**, 14, 2415-2431	3.6	19
76	Epilepsy biomarkers - Toward etiology and pathology specificity. *Neurobiology of Disease*, **2019**, 123, 42-58	7.5	74
75	Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors. *Advances in Therapy*, **2019**, 36, 2638-2678	4.1	86
74	State of the Art of Natural Killer Cell Imaging: A Systematic Review. *Cancers*, **2019**, 11,	6.6	6
73	Road map to best practices. **2019**, 241-273		0
72	Landscape of granted US patents in personalized diagnostics for oncology from 2014 to 2018. *Expert Opinion on Therapeutic Patents*, **2019**, 29, 191-198	6.8	0
71	Assessing the Joint Value of Genomic-Based Diagnostic Tests and Gene Therapies. *Journal of Personalized Medicine*, **2019**, 9,	3.6	4

70	Biomicrofluidic Systems for Hematologic Cancer Research and Clinical Applications. *SLAS Technology*, **2019**, 24, 457-476	3	6
69	Expression of programmed death ligand (PD-L1) in different tumors. Comparison of several current available antibody clones and antibody profiling. *Annals of Diagnostic Pathology*, **2019**, 41, 24-37	2.2	25
68	Implementation of collagen biomarkers in the clinical setting. **2019**, 373-384		
67	Immunohistochemistry. **2019**, 53-91		0
66	Next-Generation Sequencing–Based Companion Diagnostics: From Biomarker Discovery to Clinical Implementation. **2019**, 135-163		
65	Current Status and Future Direction of Companion Diagnostics. **2019**, 455-472		1
64	The Role of Biomarkers in Alzheimer's Disease Drug Development. *Advances in Experimental Medicine and Biology*, **2019**, 1118, 29-61	3.6	40
63	Immunohistochemical detection of PD-L1 among diverse human neoplasms in a reference laboratory: observations based upon 62,896 cases. *Modern Pathology*, **2019**, 32, 929-942	9.8	38
62	Engineered T Cell Therapies from a Drug Development Viewpoint. *Engineering*, **2019**, 5, 140-149	9.7	7
61	PD-L1 Detection-Pearls and Pitfalls Associated With Current Methodologies Focusing on Entities Relevant to Dermatopathology. *American Journal of Dermatopathology*, **2019**, 41, 539-565	0.9	6
60	Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP). *Applied Immunohistochemistry and Molecular Morphology*, **2019**, 27, 699-714	1.9	23
59	Analytical Validation and Clinical Utility of an Immunohistochemical Programmed Death Ligand-1 Diagnostic Assay and Combined Tumor and Immune Cell Scoring Algorithm for Durvalumab in Urothelial Carcinoma. *Archives of Pathology and Laboratory Medicine*, **2019**, 143, 722-731	5	11
58	Predictive Biomarkers and Targeted Therapies in Immuno-oncology. **2019**, 335-344		1
57	Quality Control of Immunohistochemical and In Situ Hybridization Predictive Biomarkers for Patient Treatment: Experience from International Guidelines and International Quality Control Schemes. **2019**, 525-537		1
56	Size matters: Dissecting key parameters for panel-based tumor mutational burden analysis. *International Journal of Cancer*, **2019**, 144, 848-858	7.5	78
55	Programmed Cell Death 1 and Programmed Cell Death Ligands in Extranodal Natural Killer/T Cell Lymphoma: Expression Pattern and Potential Prognostic Relevance. *Acta Haematologica*, **2020**, 143, 78-88	2.7	10
54	The Cancer Immunotherapy Biomarker Testing Landscape. *Archives of Pathology and Laboratory Medicine*, **2020**, 144, 706-724	5	30
53	The Ongoing Search for Biomarkers of CDK4/6 Inhibitor Responsiveness in Breast Cancer. *Molecular Cancer Therapeutics*, **2020**, 19, 3-12	6.1	23

52	External quality assessment demonstrates that PD-L1 22C3 and SP263 assays are systematically different. *Journal of Pathology: Clinical Research*, **2020**, 6, 138-145	5.3	12
51	Immune contexture analysis in immuno-oncology: applications and challenges of multiplex fluorescent immunohistochemistry. *Clinical and Translational Immunology*, **2020**, 9, e1183	6.8	12
50	BRCA-Companion-Diagnostik bei Brust- und Eierstockkrebs. *Best Practice Onkologie*, **2020**, 15, 176-182	0	
49	Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives. *International Immunopharmacology*, **2020**, 85, 106639	5.8	43
48	Upregulation of programmed death ligand 1 by liver kinase B1 and its implication in programmed death 1 blockade therapy in non-small cell lung cancer. *Life Sciences*, **2020**, 256, 117923	6.8	11
47	Update on molecular companion diagnostics - a future in personalized medicine beyond Sanger sequencing. *Expert Review of Molecular Diagnostics*, **2020**, 20, 637-644	3.8	4
46	Predictive biomarkers in clinical practice: State of the art and perspectives in solid tumors. *International Journal of Biological Markers*, **2020**, 35, 16-19	2.8	
45	Value of Precision Medicine in Advanced Non-Small Cell Lung Cancer: Real-World Outcomes Associated with the Use of Companion Diagnostics. *Oncologist*, **2020**, 25, e1743-e1752	5.7	7
44	Integrating Diagnostic Products Into the Drug Development Workflow: Applications for Companion Diagnostics. **2020**, 359-370		
43	Companion and complementary diagnostics for infectious diseases. *Expert Review of Molecular Diagnostics*, **2020**, 20, 619-636	3.8	2
42	Reimbursement and Payment Models for Therapies With Transformative and Curative Intent. **2020**, 705-745		
41	Prognostic and clinicopathological significance of PD-L1 overexpression in oral squamous cell carcinoma: A systematic review and comprehensive meta-analysis. *Oral Oncology*, **2020**, 106, 104722	4.4	30
40	Formalin fixation for optimal concordance of programmed death-ligand 1 immunostaining between cytologic and histologic specimens from patients with non-small cell lung cancer. *Cancer Cytopathology*, **2021**, 129, 304-317	3.9	3
39	Novel uses of immunohistochemistry in breast pathology: interpretation and pitfalls. *Modern Pathology*, **2021**, 34, 62-77	9.8	15
38	A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases. *Modern Pathology*, **2021**, 34, 252-263	9.8	25
37	Liquid biopsy enters the clinic - implementation issues and future challenges. *Nature Reviews Clinical Oncology*, **2021**, 18, 297-312	19.4	158
36	Precision Medicine. **2021**, 115-120		
35	A Decade of FDA-Approved Drugs (2010-2019): Trends and Future Directions. *Journal of Medicinal Chemistry*, **2021**, 64, 2312-2338	8.3	41

34	PD-L1 as a biomarker of response to immune-checkpoint inhibitors. *Nature Reviews Clinical Oncology*, **2021**, 18, 345-362	19.4	148
33	A survey of cancer genome signatures identifies genes connected to distinct chromosomal instability phenotypes. *Pharmacogenomics Journal*, **2021**, 21, 390-401	3.5	1
32	Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry. *Pathology and Oncology Research*, **2021**, 27, 592997	2.6	4
31	PIK3CA Mutation Assessment in HR+/HER2Metastatic Breast Cancer: Overview for Oncology Clinical Practice. *Journal of Molecular Pathology*, **2021**, 2, 42-54	0.4	3
30	Programmed cell death-ligand 1 assessment in urothelial carcinoma: prospect and limitation. *Journal of Pathology and Translational Medicine*, **2021**, 55, 163-170	2.9	3
29	Prognostic prospect of soluble programmed cell death ligand-1 in cancer management. *Acta Biochimica Et Biophysica Sinica*, **2021**, 53, 961-978	2.8	2
28	False-negative programmed death-ligand 1 immunostaining in ethanol-fixed endobronchial ultrasound-guided transbronchial needle aspiration specimens of non-small-cell lung cancer patients. *Histopathology*, **2021**, 79, 480-490	7.3	3
27	Induced Pluripotent Stem Cell-Based Systems for Personalising Epilepsy Treatment: Research Ethics Challenges and New Insights for the Ethics of Personalised Medicine. *AJOB Neuroscience*, **2021**, 1-12	0.8	2
26	Tissue Multiplex Analyte Detection in Anatomic Pathology - Pathways to Clinical Implementation. *Frontiers in Molecular Biosciences*, **2021**, 8, 672531	5.6	4
25	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. **2021**, 9,		7
24	Development of Gene Expression-Based Biomarkers on the nCounter Platform for Immuno-Oncology Applications. *Methods in Molecular Biology*, **2020**, 2055, 273-300	1.4	2
23	Targeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy: A new clinical paradigm in the treatment of triple-negative breast cancer. *Bosnian Journal of Basic Medical Sciences*, **2019**, 19, 227-233	3.3	55
22	Exploring the Potential of Drug Response Assays for Precision Medicine in Ovarian Cancer. *International Journal of Molecular Sciences*, **2020**, 22,	6.3	6
21	Benefits of functional assays in personalized cancer medicine: more than just a proof-of-concept. *Theranostics*, **2021**, 11, 9538-9556	12.1	0
20	Companion Diagnostics: State of the Art and New Regulations. *Biomarker Insights*, **2021**, 16, 11772719211047763	3.9	3
19	Regulating innovation in the early development of cell therapies. *Immunotherapy Advances*, **2021**, 1,		0
18	Clinical pharmacogenetics. **2022**, 189-212		
17	Integrating Molecular Biomarker Inputs Into Development and Use of Clinical Cancer Therapeutics. *Frontiers in Pharmacology*, **2021**, 12, 747194	5.6	3

16	High-Field Asymmetric Waveform Ion Mobility Spectrometry and Parallel Reaction Monitoring Increases Sensitivity for Clinical Biomarker Quantitation from Formalin-Fixed, Paraffin-Embedded Tumor Biopsies.		
15	Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma.. *Frontiers in Pharmacology*, **2022**, 13, 869488	5.8	0
14	Companion Diagnostics.. *Archives of Pathology and Laboratory Medicine*, **2022**,	5	
13	Overview of Immunohistochemistry Assessment of Cancer-Related Predictive Biomarkers and Common Genetic Alterations. **2022**, 131-160		
12	Precision Medicine: An Optimal Approach to Patient Care in Renal Cell Carcinoma. *Frontiers in Medicine*, 9,	4.9	1
11	Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges. *British Journal of Cancer*,	8.7	0
10	Implications of Precision Medicine on Marketing and Sales Strategies. *Management for Professionals* , **2022**, 29-42	0.4	
9	Molecular Biomarkers in Cancer. *Biomolecules*, **2022**, 12, 1021	5.9	2
8	The addition of FAIMS increases targeted proteomics sensitivity from FFPE tumor biopsies. **2022**, 12,		0
7	Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types. **2022**, 10, e005573		1
6	The Anticancer Power of the Immune System New Perspectives for Patients with Triple-Negative Breast Cancer. 54-62		0
5	Assessing PD-L1 Expression in Different Tumor Types. **2023**, 1-21		0
4	Companion diagnostic requirements for spatial biology using multiplex immunofluorescence and multispectral imaging. 10,		0
3	Next-generation liquid biopsy instruments: Challenges and opportunities.		0
2	Lymphocyte-activating gene 3 expression in tumor cells predicts immune checkpoint inhibitor response in triple negative breast cancer. 13,		0
1	Drug discovery processes: When and where the rubber meets the road. **2023**, 339-415		0